anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: The ambulance service plays a pivotal role in the provision of care in out-of-hospital maternity emergencies. Telephone triage of this patient group is complex and must be sensitive to an emergency situation to prevent unnecessary delays in treatment. This study aimed to explore emergency medical dispatchers' (EMDs) perceptions of the structured protocol they use.
DESIGN: Voluntary participation in semistructured phenomenological focus groups. The participants were asked to discuss their experiences of using Medical Priority Dispatch System Protocol 24 (pregnancy, childbirth and miscarriage). Thematic analysis was applied to code and group topics. Discussion between the EMDs is presented for each theme and their experiences, including quotes, are presented to offer an overview of the maternity protocol and its use.
SETTING: A large urban UK ambulance service.
PARTICIPANTS: 23 control room staff.
RESULTS: Perceptions of maternity emergencies, challenges with key questions, the need for sensitivity surrounding miscarriage, using prearrival instructions and postdispatch instructions to help patients and ideas for additional ProQA functionality emerged as the five overarching themes. Protocol 24 was considered to reflect many of the clinical factors EMDs associate with maternity emergencies although further factors, including some non-clinical, were suggested for inclusion. Miscarriage and termination-related calls were thought to be challenging as the language of the protocol is designed for pregnancy. However, instructions were generally considered well written and user-friendly, although some were thought to be unnecessary. EMDs were largely positive regarding the ProQA software, but felt backward navigation was difficult if a situation changed.
CONCLUSIONS: Maternity calls were considered rewarding but complex by EMDs. We suggest changes including the use of more sensitive language in response to miscarriage and termination and make recommendations for the omission and inclusion of specific instructions, as well as enhancements to key questions and functionality. Further research is needed to ensure focus group findings are generalisable to other services, particularly in other countries.
PURPOSE:To obtain the deodorant applicable for intraoral use in a wide range by using the high-polymer fraction of a specific mol.wt. obtd. by protease decomposition of separated soy bean protein as the effective component. CONSTITUTION:Dry green soy beans are roughly ground and after the skin is removed therefrom, the soy beans are further ground to <=30 mesh powder. The powder is degreased by using n-hexane or a soln. mixture composed of methanol and chloroform as a solvent and is dissolved by a weakly alkaline soln. The soln. is subjected to a solid-liquid sepn. by a centrifugal sepn. or the like by which the undissolved matter is removed. The pH of the supernatant liquid thereof is controlled to weak acidity to allow the protein to settle and the protein is subjected to the solid-liquid sepn. by the centrifugal sepn. or the like. The separated solid is freeze-dried after washing with water and is separated by which the soy bean protein is obtd. This protein is sufficiently decomposed by the protease and after the oxygen is deactivated, the protein is subjected to the solid-liquid sepn. by the centrifugal sepn. or the like. The residues thereof are dissolved again in the alkaline soln. of the weak alkalinity and <100000 fractions are removed by an ultrafilter membrane of 100000mol.wt. The remaining soln. of >=100000 fractions is subjected to isoelectric point precipitation to recover the protein. After the protein is thoroughly washed with water, the protein is freeze- dried.
INTRODUCTION: Pregnancy complications, including preeclampsia (PE), preterm birth (PTB), and intra-uterine growth restriction (IUGR) have individually been associated with inflammation but the combined comparative analysis of their placental profiles at the transcriptomic and histological levels is lacking.
METHODS: Bulk RNA-sequencing of human placental biopsies from uncomplicated term pregnancies (CTL) and pregnancies complicated with early-onset (EO), and late-onset (LO) PE, as well as PTB and term IUGR were used to characterize individual molecular profiles. We also applied immune-cell-specific cellular deconvolution to address local immune cell compositions and analyzed placental lesions by histology to further characterize these complications.
RESULTS: Transcriptome analysis revealed that clinically distinct complications differentiated themselves in unique ways compared to CTLs. Only TMEM136 was commonly modulated. Compared to CTLs, we found that PTB and IUGR were the most distinct, with LOPE being the least distinct. PTB and IUGR revealed differently enhanced inflammatory pathways, where PTB had general inflammatory responses and IUGR had immune cell activation. This inflammation was reflected in the histological profile for PTB only, whereas structural lesions were elevated in all complications. Placental lesions additionally had corresponding enhancement in inflammatory and structural biological processes. We observed that having co-complications, particularly for PTB with or without IUGR, impacted placental transcriptomes. Lastly, cellular deconvolution uncovered shared immune features among the complications.
DISCUSSION: Overall, we provide evidence that these pregnancy complications are not only distinct in their clinical manifestations but also in their placental profiles, which could be leveraged to understand their underlying mechanisms and could offer therapeutic targets.
NEW MATERIAL:Human antibody gene fragments consisting of nucleotide sequence expressed by DNA base pairs consisting of DNA base units expressed by the formula and complementary bases thereto. USE:A starting material for hybrid DNA integrable into various vectors by combination with human H chain protein gene. PREPARATION:For example, a human cultivated cell ARH77 strain as a starting strain is used to isolate human chromosome DNA, which is then partially digested with a restriction endonuclease EcoRI to give the corresponding DNA fragments. The resultant DNA fragments are then linked to prepare a human lambdagene library. A plaque is then formed, etc. to screen human antibody gene. The resultant Charon 4A DNA containing the human antibody gene is then dissolved in a restriction endonuclease digestion buffer. After digestion, electrophoresis is carried out to prepare a restriction cleavage map. The recloning of the human antibody is carried out to make the intracellular expression of the human antibody gene.
BACKGROUND: Preterm birth (PTB) affects ∼15 million pregnancies worldwide. Genetic studies have identified several candidate loci for PTB, but results remain inconclusive and limited to European populations. Thus, we conducted a genome-wide association study (GWAS) of PTB and gestational age at delivery (GA) among 2,212 Peruvian women.
METHODS: PTB cases delivered≥20 weeks' but < 37 weeks' gestation, while controls delivered at term (≥37 weeks but <42 weeks). Multivariable regressions were used to identify genetic markers for PTB and GA (∼6 million SNPs), adjusting for maternal age and the first two genetic principal components. In silico functional analysis was conducted among top signals detected with an arbitrary P < 1.0×10-5 . We sought to replicate genetic markers for PTB and GA identified in Europeans, and we developed a genetic risk score for GA based on European markers.
RESULTS: Mean GA was 30 ± 4 weeks in PTB cases (N = 933) and 39 ± 1 in the controls (N = 1,279). No associatiosn were identified at genome-wide level. Nominal PTB variants were enriched for biological pathways associated with polyketide, progesterone, steroid hormones, and glycosyl metabolism. Nominal GA variants were enriched in intronic regions and cancer pathways. Variants in WNT4 associated with GA in Europeans were replicated in our study. A genetic risk score was associated with a 2-day longer GA (P = 0.002) in our sample.
CONCLUSIONS: This study identified various signals suggestively associated with PTB and GA in pregnant Peruvian women. None of these variants overlapped with signals previously identified in Europeans.
The ultimate goal of this investigation is to validate the ability of the prototype platform (miniaturized microfluidic device that can rapidly (within 15 minutes) measure small volumes of oral fluids (on the order of nanoliters of fluid) and identify biomarkers of disease such as mediators of inflammation (interleukins -1 and -6; C-reactive protein (CRP), and a marker of bone resorption (ICTP). This analysis will aid in the diagnosis of active periodontal (gum) disease as well as diseases involved in systemic inflammation (e.g., cardiovascular disease) or systemic bone loss (osteoporosis). This project will have two specific goals: 1. To validate the ability of the diagnostic to measure the designated mediators from oral fluids; and 2. Determine the ability of the multiplexed format of mediator analysis to predict disease activity (future bone loss) in patients at high and low risk for disease. This proposed feasibility study will then aid in providing the impetus for sample size and other design requirements for larger, more expanded human clinical trial testing and subsequent technology transfer.
Retinal telangiectasis is a group of rare, idiopathic retinal vascular anomalies affecting the retinal capillaries in which irregular capillary dilation and incompetence occur in the macula. This is the former group 2 in the Gass classification of idiopathic juxtafoveal telangiectasia in which fluorescein angiography showed leakage with capillary dilation. These patients typically are diagnosed in their fifth or sixth decade of life. Both sexes may be affected. Minimal exudation, superficial retinal crystalline deposits, and right-angle venules characterize this disorder. As the disease progresses, intraretinal pigment plaques and eventually subretinal/choroidal neovascularization develop. Currently, these patients will be classified as macular telangiectasia. The pathogenesis of the disease is unknown. Because of the leakage of the retinal vessels and also the finding of neovascularization, it is possible that vascular endothelial growth factor (VEGF) may be implicated in this disease.

The purpose of this study is to evaluate the possible role of ranibizumab for the treatment of five participants with macular telangiectasia with hyperfluorescence on fluorescein angiography, with vision decreased to 20/40 or worse, with neovascularization. The primary outcome will be a visual acuity change, either increase or decrease of 15 letters or more at one year. The secondary outcomes measured at one year will include visual acuity changes of 10 letters or more, the change in retinal thickening documented by OCT, the extent and degree of fluorescein leakage, the change in area of hypofluorescence, and the change in central retinal sensitivity. This is a pilot study designed to evaluate the feasibility and potential efficacy of treating patients with macular telangiectasia in a larger, phase III study within the organization of the MAC TEL Research Group, sponsored by the Lowy Foundation. Currently, the research group is enrolling 200 patients affected with this condition for a natural history study in 22 international clinical centers.
The invention relates to the field of skin care, specifically to a rice-water licorice mask and manufacturing and application methods thereof. The mask comprises the following ingredients: 40-50 g of rice, 200-240 ml of soft water and 5-10 g of licorice powder. The manufacturing method comprises the following steps: Step 1, preparing manufacturing materials and tools; Step 2, removing impurities from rice; Step 3, immersing rice; Step4, boiling rice to obtain rice water; and Step 5, cooling rice water and sealing. When the mask is used each time, 20-45 g of rice water is fetched with a teaspoon, 1 g of licorice powder is added, and the rice water and licorice powder are uniformly blended. Substances in the mask tightly coat the skin to isolate the skin from the surrounding air. Moisture slowly infiltrates into epidermal cuticle, and moisture in the mask is also prevented from being lost. Thus, it is ensured that the skin is soft and skin elasticity is increased. The rice has a whitening effect. Licorice belongs to a traditional Chinese medicine and is mild in nature. By combining rice and licorice, the skin allergy problem can be effectively solved.
Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
The present invention discloses an intravenous injection liquid containing a coenzyme Q10 and a preparing method thereof. The injection liquid is prepared from a coenzyme Q10, a solubilizing agent, injection solvent and an osmotic pressure regulating agent, wherein the coenzyme Q10 is used as an active component. The preparing method comprises the steps: the water-insoluble coenzyme Q10 is prepared into clear and transparent solution by the solubilizing agent, the injection solvent and the osmotic pressure regulating agent, and the clear and transparent solution is prepared into a preparation which meets the requirement of injections and is suitable for intravenous injection by volume determination, bacteria removal and encapsulation. The method of the present invention solves the technical problems of water insolubility and light instability of the coenzyme Q10. The injection liquid which is prepared with the method of the present invention and is used for intravenous injection has the advantages that no first pass effect is generated when the injection liquid is absorbed by a human body, the bioavailability is improved, the injection liquid is not prepared in the process of intravenous injection, the cross infection is avoided, the clinical application level and the safety of the coenzyme Q10 are improved. The injection liquid is convenient in use.
Described embodiments include a system, method, and computer program product. A described system includes a receiver circuit that receives a first medical image. The first medical image includes a selected target region of interest of an individual patient's body part, and a landmark subsurface feature of the individual patient's body part having a first spatial relationship with the selected target region. The receiver circuit receives a second medical image that includes a candidate region of interest of the individual patient's body part, and a landmark feature of the individual's patient body part having a second spatial relationship with the candidate region. A feature matching circuit determines a correspondence between the candidate landmark subsurface feature and the associated landmark subsurface feature. A reporting circuit generates informational data indicating the second medical image includes at least a portion of the selected target region of interest. A communication circuit outputs the informational data.
Individually titrate hydromorphone hydrochloride tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving hydromorphone hydrochloride tablets to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.2)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. 

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the hydromorphone hydrochloride tablets dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

For chronic pain, doses should be administered around-the-clock. A supplemental dose of 5 to 15% of the total daily usage may be administered every two hours on an as-needed basis.
Sepsis-associated encephalopathy (SAE) is a serious neurological complication accompanied with acute and long-term cognitive dysfunction. Ferroptosis is a newly discovered type of cell death that is produced by iron-dependent lipid peroxidation. Emerging evidence suggests that ferroptosis is involved in SAE. The nuclear factor erythroid 2-related factor 2 (Nrf2) is a mitochondria related gene involved in ferroptosis. However, the role of Nrf2 in SAE and the mechanisms remains elusive. In this study, we found that Nrf2 knockout aggravated cognitive and emotional dysfunction and promoted caecal ligation and puncture (CLP)-induced brain injury and hippocampus ferroptosis as indicated by the increase of ROS, Fe2+ and the levels of proinflammatory cytokines. Meanwhile, the levels of glutathione peroxidase 4 (GPX4), SLC7A11 and glutathionewere downregulatedin Nrf2 knockout group. In vitro experiments showed that mitochondrial ROS, Fe2+ and the expression of Fis1 and Drp1 decreased, and the level of Mfn1 and Opa-1 increased after Nrf2 overexpression. The silence of Nrf2 increased the expression of ROS, MDA and Fe2+, while decreased glutathione, mitochondrial membrane potential (MMP) and cell viability in vitro, indicating Nrf2 improved LPS-induced mitochondrial dysfunction and mitigated hippocampal cells ferroptosis. These results suggest that Nrf2 could inhibit ferroptosis and neuroinflammation in hippocampus and reduce cognitive dysfunction in SAE mice, making it a potential therapeutic target in the treatment of SAE. The protective effects of Nrf2 on the brain may be mediated by maintaining mitochondrial dynamic homeostasis.
Approximately one-third of patients with major depressive disorder do not achieve adequate symptom control despite a series of multiple treatment trials with currently available antidepressant medication (for example a serotonin-selective reuptake inhibitor). This group of patients - representing treatment-resistant depression (TRD) - accounts for an alarmingly high public health burden and signifies a critical area of need in pharmaceutical treatment development. While current treatments are slow to act and only partially effective, new basic and clinical research focusing on the glutamate system is yielding promising new avenues for novel drug discovery. Ketamine - a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist - has now been demonstrated in several studies to bring about a rapid and robust antidepressant effect, even in patients suffering from TRD. Ketamine is limited as a treatment for TRD by the need for intravenous administration and the potential for untoward medical or psychiatric adverse effects. There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD. The current project aims to test the safety, tolerability and efficacy of Nuedexta - containing the NMDA antagonist dextromethorphan.
Neospora caninum  is the causal agent of bovine neosporosis which results in high levels of abortion. The protective efficacy of two  Neospora  antigens:  Neospora  cyclophilin (NcCyP) and NcSRS2 was evaluated. Mice vaccinated with recombinant (r) NcCyP, rNcSRS2, and the combination rNcCyP plus rNcSRS2, formulated with adjuvant ImmuMax-SR® and CpG were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Mice vaccinated with rNcCyP, rNcSRS2, or the combination of rNcCyP and rNcSRS2 responded with high levels of NcCyP- or NcSRS2- specific antibodies. Mice which received vaccines formulated with either rNcCyP or the combination rNcCyP and rNcSRS2 had a higher (p<0.01) percent protection when compared to the mock- or non-vaccinated mice. Groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection. Results indicate that NcCyP is a highly efficacious vaccine candidate useful in protection against  Neospora  infection.
A particular uncommon isomer of retinoic acid (namely 11-cis-retinoic acid, or neotretinoin) is useful in treating conditions involving abnormal cellular differentiation and hyperproliferation, such as psoriasis. A new method of synthesizing this isomer, in quantities that has allowed it to be compared therapeutically with the more commonly available all-trans and 13-cis isomers, is presented. As measured on the inventor's own psoriasis-affected skin, topical treatment with 11-cis-retinoic acid is much more efficacious in reducing symptoms and has substantially reduced side effects, as compared to topical treatment with the other isomers. A single application of a 0.001% neotretinoin cream to psoriasis lesions leads within 48 hours to substantial amelioration of associated dermatological symptoms, including itching, scaling, bleeding, and abnormal appearance. Continued application leads to complete remission, and replacement of lesions by skin that is indistinguishable from surrounding healthy tissue, without any noticeable irritation, erythema, or other problematic side effects. A less efficacious but more easily-implemented version of the same invention employs ultraviolet or blue-light irradiation of a commercially-available gel containing tretinoin as a means of effecting partial conversion of the tretinoin to neotretinoin, prior to application of the gel to psoriasis-affected areas of skin.
1. Technical Result Improvement of technological process of manufacture of pharmaceutical composition by uniform drug distribution. 2. Essence A method comprises blending silicon dioxide and at least one pharmaceutical acceptable excipient, carrier or diluent in a high shear granulator for an appropriate amount of time to produce a blended mixture, adding an active ingredient under mixing, after which the obtained active blend is transferred from the granulator to a blender, optionally, adding one or more additional pharmaceutical acceptable excipients, carriers or diluents to the active blend, and blending for a suitable period of time to form a pharmaceutical composition having uniform distribution of the active ingredient; wherein said active ingredient is a selective estrogen receptor modulator. The method is particularly useful for the manufacture of low dosage pharmaceutical compositions. 3. Field of Application Medicine. Tables: 1
This invention is based in part on the discovery that miR-34 is independent of p53. It has been discovered that miR-34 functions in a TP53-independent tumor suppression pathway. Specifically, miR-34-induced inhibition of cancer cell growth was found to be the same in p53-normal and p53-deficient cells. Thus, miR-34 has a more central role during tumor suppression that is uncoupled from p53. In the absence of p53, miR-34, unlike certain other miRNAs, is sufficient to induce an up-regulation of genes known to be regulated by p53, including but not limited to p21 CIP1/WAF1  (CDKN1A), PUMA, BAX, NOXA, PHLDA3, and MDM2 and a down-regulation of HDAC1. Therefore, these biomarkers can be used as biomarkers of miR-34 activity. The invention is further based on the discovery that some of these biomarkers are indispensable for a therapeutic response to miR-34 activity, and are thus prerequisite biomarkers of miR-34 activity.